These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1067 related articles for article (PubMed ID: 30249646)
1. Small molecule inhibits α-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons. Pujols J; Peña-Díaz S; Lázaro DF; Peccati F; Pinheiro F; González D; Carija A; Navarro S; Conde-Giménez M; García J; Guardiola S; Giralt E; Salvatella X; Sancho J; Sodupe M; Outeiro TF; Dalfó E; Ventura S Proc Natl Acad Sci U S A; 2018 Oct; 115(41):10481-10486. PubMed ID: 30249646 [TBL] [Abstract][Full Text] [Related]
2. The small aromatic compound SynuClean-D inhibits the aggregation and seeded polymerization of multiple α-synuclein strains. Peña-Díaz S; Pujols J; Vasili E; Pinheiro F; Santos J; Manglano-Artuñedo Z; Outeiro TF; Ventura S J Biol Chem; 2022 May; 298(5):101902. PubMed ID: 35390347 [TBL] [Abstract][Full Text] [Related]
3. Structural Features and Toxicity of α-Synuclein Oligomers Grown in the Presence of DOPAC. Palazzi L; Fongaro B; Leri M; Acquasaliente L; Stefani M; Bucciantini M; Polverino de Laureto P Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34199427 [TBL] [Abstract][Full Text] [Related]
11. Anti-Parkinsonian effects of Bacopa monnieri: insights from transgenic and pharmacological Caenorhabditis elegans models of Parkinson's disease. Jadiya P; Khan A; Sammi SR; Kaur S; Mir SS; Nazir A Biochem Biophys Res Commun; 2011 Oct; 413(4):605-10. PubMed ID: 21925152 [TBL] [Abstract][Full Text] [Related]
12. Phenotypic manifestation of α-synuclein strains derived from Parkinson's disease and multiple system atrophy in human dopaminergic neurons. Tanudjojo B; Shaikh SS; Fenyi A; Bousset L; Agarwal D; Marsh J; Zois C; Heman-Ackah S; Fischer R; Sims D; Melki R; Tofaris GK Nat Commun; 2021 Jun; 12(1):3817. PubMed ID: 34155194 [TBL] [Abstract][Full Text] [Related]
13. Two-step screening method to identify α-synuclein aggregation inhibitors for Parkinson's disease. Hideshima M; Kimura Y; Aguirre C; Kakuda K; Takeuchi T; Choong CJ; Doi J; Nabekura K; Yamaguchi K; Nakajima K; Baba K; Nagano S; Goto Y; Nagai Y; Mochizuki H; Ikenaka K Sci Rep; 2022 Jan; 12(1):351. PubMed ID: 35013421 [TBL] [Abstract][Full Text] [Related]
14. Defining α-synuclein species responsible for Parkinson's disease phenotypes in mice. Froula JM; Castellana-Cruz M; Anabtawi NM; Camino JD; Chen SW; Thrasher DR; Freire J; Yazdi AA; Fleming S; Dobson CM; Kumita JR; Cremades N; Volpicelli-Daley LA J Biol Chem; 2019 Jul; 294(27):10392-10406. PubMed ID: 31142553 [TBL] [Abstract][Full Text] [Related]
15. The Parkinson's disease-related protein DJ-1 protects dopaminergic neurons in vivo and cultured cells from alpha-synuclein and 6-hydroxydopamine toxicity. Batelli S; Invernizzi RW; Negro A; Calcagno E; Rodilossi S; Forloni G; Albani D Neurodegener Dis; 2015; 15(1):13-23. PubMed ID: 25500798 [TBL] [Abstract][Full Text] [Related]
16. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons. Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146 [TBL] [Abstract][Full Text] [Related]
17. The Small GTPase RAC1/CED-10 Is Essential in Maintaining Dopaminergic Neuron Function and Survival Against α-Synuclein-Induced Toxicity. Kim H; Calatayud C; Guha S; Fernández-Carasa I; Berkowitz L; Carballo-Carbajal I; Ezquerra M; Fernández-Santiago R; Kapahi P; Raya Á; Miranda-Vizuete A; Lizcano JM; Vila M; Caldwell KA; Caldwell GA; Consiglio A; Dalfo E Mol Neurobiol; 2018 Sep; 55(9):7533-7552. PubMed ID: 29429047 [TBL] [Abstract][Full Text] [Related]
18. Synthetic alpha-synuclein fibrils cause mitochondrial impairment and selective dopamine neurodegeneration in part via iNOS-mediated nitric oxide production. Tapias V; Hu X; Luk KC; Sanders LH; Lee VM; Greenamyre JT Cell Mol Life Sci; 2017 Aug; 74(15):2851-2874. PubMed ID: 28534083 [TBL] [Abstract][Full Text] [Related]
19. Chemical Chaperones as Novel Drugs for Parkinson's Disease. Pujols J; Peña-Díaz S; Pallarès I; Ventura S Trends Mol Med; 2020 Apr; 26(4):408-421. PubMed ID: 32277934 [TBL] [Abstract][Full Text] [Related]
20. The effect of mutant GBA1 on accumulation and aggregation of α-synuclein. Maor G; Rapaport D; Horowitz M Hum Mol Genet; 2019 Jun; 28(11):1768-1781. PubMed ID: 30615125 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]